SCHEMBL15959532

SCHEMBL15959532

CCOC(=O)c1sc(CBr)cc1NC(=O)Nc1ccc(C)cc1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 4/20 0.83
MAPK14 Q16539 10/20 0.69
MEN1 O00255 5/20 0.57
KMT2A Q03164 5/20 0.57
MAPT P10636 3/20 0.57
LMNA P02545 2/20 0.57
HTT P42858 2/20 0.57
HPGD P15428 2/20 0.57
ALDH1A1 P00352 1/20 0.57
PLA2G1B P04054 1/20 0.57
ATG4B Q9Y4P1 1/20 0.57
MCL1 Q07820 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
NPC1 O15118 2/20 0.49
NFKB1 P19838 2/20 0.49
RAB9A P51151 2/20 0.49
NFKB2 Q00653 2/20 0.49
RELA Q04206 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
USP2 O75604 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2926566 0.91 RAF1 (1.00) RAF1MAPK14MAPTALDH1A1PKM
SCHEMBL14159719 0.89 MAPK14 (0.66) RAF1MAPK14MEN1KMT2AMAPT
SCHEMBL14159658 0.85 RAF1 (0.78) RAF1MAPK14MEN1KMT2AMAPT
SCHEMBL3217455 0.82 RAF1 (0.80) RAF1MAPK14MAPTALDH1A1PKM
SCHEMBL3217460 0.81 MAPK14 (1.00) RAF1MAPK14
SCHEMBL10275911 0.78 RAF1 (0.77) RAF1MAPK14MEN1KMT2AMAPT
SCHEMBL15298832 0.77 RAF1 (0.75) RAF1MAPK14MAPTALDH1A1PKM
SCHEMBL6473441 0.77 RAF1 (0.61) RAF1MAPK14MEN1KMT2AMAPT
SCHEMBL3239006 0.74 MAPK14 (1.00) RAF1MAPK14
SCHEMBL4113307 0.72 MAPT (0.77) MEN1KMT2AMAPTALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140234324-A1 METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2014-08-21 US disclosed
US-20140234324-A1 METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2014-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140234324-A1 METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 LY96, HSPA2, BRAF RAF1 77/4885MAPK14 1605/4885MEN1 3767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.